A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Clinical trial NCT07701941 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07701941
- Sponsor
- Daiichi Sankyo
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-03
- Primary completion
- 2031-01-01
- Enrollment
- 220
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.